result upgrad ep mostli lower futur
tax rate hike pt given tax benefit new npv
anti-tau move directli phase ep remain
ahead rise con con upgrad conceiv long-term
padsevonil phase iib data drug-resist epilepsi like march potenti
worth npv posit retain buy
still signific upsid rise consensu trim revenu larg
lower legaci keppra sale revis model even profit-shar
op incom cimzia vimpat sale upgrad ep cut
higher opex off-set futur year mid-teen
tax rate ep upgrad earn remain
ahead rise consensu upsid remain substanti
consensu upgrad possibl hike npv-deriv price
mostli lower tax rate benefit plu npv
contribut anti-tau enter phase progress supranuclear
initi outlook like conserv assum modest cimzia growth
revenu estim still aim top-lin
beaten target consist sinc new cfo start shortli see
room upgrad rebitda margin alreadi factor dilut
ra pharma acquisit due close shortli henc aim
revis vimpat peak sale aim achiev jefe
continu assum cimzia peak shi manag
give greater confid upcom wave potenti blockbust product
launch help sustain growth even key product slow/declin
face increas competit patent expiri see blockbust potenti
even osteoporosi ww peak ramping-up strongli us
japan led partner bimekizumab approv psoriasi
albeit fierc competit greater potenti psoriat arthriti
ankylos spondyl phase data ww peak zilucoplan
generalis myasthenia gravi gmg phase data arguabl de-
risk view launch ww peak
adjust contribut three late-stag programm padsevonil treat
highli drug-resist epilepsi probabl ww peak sale ahead
upcom phase iib aris data rozanolixizumab anti-fcrn igg-medi
autoimmun disord probabl key cidp indic
anti-tau ab psp includ daprolizumab lupu due start
phase partner given prior mix phase iib earlier stage
defin ucb ep
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
defin ucb ebit
defin ucb ep
blockbust even bimekizumab zilucoplan
off-set slow-to-declin sale key product
includ cimzia vimpat neupro briviact
remain conserv padsevonil epilepsi
includ npv contribut anti-tau anti-
alpha synuclein dapirolizumab enter phase
share
in-lin eu mid-cap
biopharma peer per share
price base npv impli pe
minim impact cimzia sale growth futur
anti-tnf biosimilar oral could add around
allow file launch could
bimekizumab approv psoriasi
rozanolixizumab padsevonil could togeth add
catalyst next could boost
npv sum-of-the-part valuat
rapid cimzia declin could lower npv
valuat
efficaci safeti concern zilucoplan could
efficaci safeti concern bimekizumab could
remov
remov
pipelin setback notabl rozanolixizumab
padsevonil could togeth remov
potenti setback next month could
reduc npv sum-of-the-part valuat
increasingli confid wave new
potenti blockbust product launch
next year off-set slow-
to-declin sale key product continu
near-term
sustain growth trajectori busi
misplac forecast
consensu revenu ep
forecast suggest ep
around march phase data
potenti aad march cosentyx head-
to-head data file
approv launch phase
data
data launch
rozanolixizumab phase gmg data phase ii
pleas see import disclosur inform page report
buy price target
increasingli confid wave new potenti blockbust product
launch next year off-set slow-to-declin sale key
product continu pipelin invest believ concern around near-term
sustain growth trajectori busi misplac recent pipelin
develop help drive near-term revenu ep growth includ
posit phase bimekizumab data initi launch psoriasi
surpris welcom european approv even osteoporosi expect launch
immin addit zilucoplan myasthenia gravi pipelin
sensibl acquisit ra pharma potenti launch help
drive consensu forecast suggest sustain near-term growth even
increas biosimilar competit cimzia loss exclus neupro
vimpat well flag ucb current trade in-lin eu mid-
cap biopharma peer per share price base npv impli
pe premium peer believ warrant given robust
growth superior pipelin option
per share price base npv sum-of-the-part valuat
could increas per share includ potenti upsid catalyst notabl
rozanolixizumab clinic data posit suffici file across three main
indic howev could downsid risk pipelin setback includ
zilucoplan bimkizumab rozanolixizumab
pleas see import disclosur inform page report
peakvalueadj valueeurindicationsal mn eurmn prob eurmn per diseas incl diseas restless leg midazolam nasal spray acut repetit ankylos gmg cidp prob focal anti-tau mab supranuclear ip market equiti research
exhibit sourc upsid potenti downsid risk
pleas see import disclosur inform page report
eureurupsidep sharedownsidep sharecimzia net price eros anti-tnf biosimilarsminim impact rapid phase gmg resultsposit regulatori and/or safeti phase iib drug-resist epilepsyposit regulatori phase ii cidp phase gmg/itp dataposit regulatori and/or safeti regulatori and/or safeti exhibit ucb catalyst
pleas see import disclosur inform page report
pleas see import disclosur inform page report
million dec us keppra european keppra row keppra us vimpat ex-u vimpat us briviact ex-u briviact us neupro ex-u neupro nayzilam midazolam nasal anti-tau incl zyrtec incl cirru cimzia cdp us cimzia cdp ex-u cimzia cdp even romosozumab roza mab prob itp gmg zilucoplan prob beyond sale like-for-lik prob sale prob revenu incl m/ group revenu prob chang year yearneurolog metad cdn/a n/a n/a n/a n/a n/a n/a n/a incl zyrtec incl cirru cimzia cdp tussionexn/a n/a n/a n/a n/a n/a n/a n/a net sale like-for-lik prob fx l/c group revenu prob exhibit ucb profit loss model
pleas see import disclosur inform page report
million except ep dec net royalti oper sale market gener admin o/w acq n-relat oper oper associ pre-tax incom continu incom discontinu net net basic share share dilut ep ep ep adjust ep paid dividend per share interim/fin chang year oper sale market gener admin oper pre-tax net ep ep adjust ep equiti research
pleas see import disclosur inform page report
 market admin oper million dec incom continu equiti share-bas net interest incom tax minor adjust non- ebitda decrease/ increas decrease/ increas increase/ decreas oper tangibl fix sale intang receiv invest dividend financ financ fx net exhibit ucb balanc sheet model
pleas see import disclosur inform page report
eur million dec plant incom tax receiv incl incom current liabil incl incom current non-curr tax sharehold premium account treasuri reserv liabil sharehold equiti research
ucb global biopharmaceut compani establish acquisit celltech schwarz pharma
compani focus two core therapeut area immunolog use small molecul biolog legaci
product includ vimpat epilepsi cimzia rheumatoid arthriti crohn diseas autoimmun disord neupro
parkinson diseas upcom wave potenti blockbust product launch includ even post-menopaus
osteoporosi bimekizumab psoriasi psoriat arthriti ankylos spondyl zilucoplan generalis myasthenia
price base npv sum-of-the-part valuat risk includ increas competit and/or reimbursement/
price pressur core product acceler impact cimzia biosimilar pipelin setback notabl zilucoplan
bimekizumab rozanolixizumab
price target base appli histor industri multipl ntm non-gaap ep support dcf risk
includ ip litig biosimilar price competit
pt base appli price-to-earnings multipl non-gaap ep support dcf risk includ ip litig
biosimilar price competit
peter welford cfa certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
philippa gardner eng certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli
indirectli relat specif recommend view express research report
luci codrington certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
colin white phd certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
registr non-u analyst peter welford cfa employ jefferi intern limit non-u affili jefferi
llc registered/qualifi research analyst finra analyst may associ person jefferi
llc finra member firm therefor may subject finra rule restrict commun
subject compani public appear trade secur held research analyst
registr non-u analyst philippa gardner eng employ jefferi intern limit non-u affili
jefferi llc registered/qualifi research analyst finra analyst may associ person
jefferi llc finra member firm therefor may subject finra rule restrict commun
subject compani public appear trade secur held research analyst
registr non-u analyst luci codrington employ jefferi intern limit non-u affili jefferi llc
registered/qualifi research analyst finra analyst may associ person jefferi llc
finra member firm therefor may subject finra rule restrict commun subject
compani public appear trade secur held research analyst
registr non-u analyst colin white phd employ jefferi intern limit non-u affili jefferi llc
registered/qualifi research analyst finra analyst may associ person jefferi llc
finra member firm therefor may subject finra rule restrict commun subject
compani public appear trade secur held research analyst
pleas see import disclosur inform page report
